The von Hippel-Lindau (VHL) syndrome is a familial cancer syndrome characterized by the development of retinal angiomata, cerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas,. A partial cDNA for the VHL gene was isolated by Michael Lerman and coworkers in 1993 and appears to be altered in both sporadic and inherited forms of renal carcinoma. The goals of this project are to gain mechanistic insights into the function(s) of the VHL protein (pVHL) and to understand how the loss of those function(s) contribute to neoplasia. Monoclonal antibodies will be raised against the VHL protein to facilitate studies of pVHL in vivo. The investigators have recently demonstrated that reintroduction of a wild (wt), but not a mutant, pVHL into renal carcinoma cells which lack endogenous wt pVHL suppressed their ability to form tumors in nude mice. A second goal of this proposal is to further refine the nude mouse assay and, if possible, develop cell culture based assays for pVHL function. In addition, two cellular proteins, p14 and p18 have been identified, which bind specifically to a 15 residue sequence in pVHL which is frequently altered by naturally occurring, presumed loss of function, VHL gene mutations. This raises the possibility that binding to p14 and p18 is necessary, and perhaps even sufficient, for tumor suppression by pVHL. To test this hypothesis, it will be asked whether specifically engineered pVHL mutants which do or do not bind to p14/p18 can suppress tumor cell growth in the nude mouse assay and, if such assays can be developed, in cell culture. In addition peptide microsequence data for p18 has been obtained and it appears to be a novel protein. The plan is to clone the cDNAs for p15 and p18, using classical reverse genetics, in hopes that their identities may provide insights into pVHL function. Furthermore, these cDNAs will likely be invaluable reagents for further exploring the functional significance of pVHL binding to these two proteins.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA068490-05
Application #
6172797
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mietz, Judy
Project Start
1996-08-01
Project End
2001-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
5
Fiscal Year
2000
Total Cost
$104,302
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Chakraborty, Abhishek A; Nakamura, Eijiro; Qi, Jun et al. (2017) HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Sci Transl Med 9:
Briggs, Kimberly J; Koivunen, Peppi; Cao, Shugeng et al. (2016) Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell 166:126-39
Olenchock, Benjamin A; Moslehi, Javid; Baik, Alan H et al. (2016) EGLN1 Inhibition and Rerouting of ?-Ketoglutarate Suffice for Remote Ischemic Protection. Cell 164:884-95
Zhang, Jing; Wang, Chengyang; Chen, Xi et al. (2015) EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer. EMBO J 34:2953-70
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90
Lu, Gang; Zhang, Qing; Huang, Ying et al. (2014) Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell 26:222-34
Lu, Gang; Middleton, Richard E; Sun, Huahang et al. (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343:305-9
Couvé, Sophie; Ladroue, Charline; Laine, Elodie et al. (2014) Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. Cancer Res 74:6554-64
Choueiri, T K; Pal, S K; McDermott, D F et al. (2014) A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 25:1603-8
Zheng, Xingnan; Zhai, Bo; Koivunen, Peppi et al. (2014) Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev 28:1429-44

Showing the most recent 10 out of 37 publications